Business Context and Reporting Period
Company: Cyclacel Pharmaceuticals, Inc. (Note: Metadata listed "Bio Green Med Solution, Inc." but the filing text identifies Cyclacel Pharmaceuticals, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: September 24, 2013
Event: Execution of an Exchange and Release Agreement with a stockholder.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on a capital structure transaction.
- Common Stock Issued: 170,818 shares ($0.001 par value).
- Preferred Stock Surrendered: 85,409 shares of 6% Exchangeable Convertible Preferred Stock.
- Remaining Preferred Stock Outstanding: 335,273 shares.
Material Changes
The material change reported is the reduction of outstanding Preferred Stock and the corresponding increase in Common Stock resulting from the exchange transaction settled on September 24, 2013. No financial performance changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Transaction Details: The exchange was initiated by the stockholder (a non-affiliate) and negotiated at arm's length. The issuance relied on the Section 3(a)(9) exemption from registration under the Securities Act of 1933, as no commission was paid for soliciting the exchange.
Risks/Contingencies: The filing does not disclose specific risks, contingencies, or forward-looking guidance beyond the completion of this specific transaction.
Investor Verification Checklist
- Verify the total number of outstanding shares of Common Stock post-transaction.
- Confirm the remaining 335,273 shares of 6% Exchangeable Convertible Preferred Stock and their conversion terms.
- Review the company's most recent 10-Q or 10-K for financial performance data, as this 8-K contains no financial statements.
- Check for any subsequent filings regarding the impact of this exchange on dilution or capitalization.